The International Pharmaceutical Research Center (IPRC) has implemented a Thermo Scientific Watson LIMS to improve the productivity and regulatory compliance of its Phase I clinical trials unit.
The Watson LIMS is a specialised, protocol-driven LIMS for drug metabolism and pharmacokinetic (DMPK) studies, which is claimed to be used as standard in bioanalytical laboratories in 18 of the top 20 global pharmaceutical companies and contract research organisations (CROs).
It is designed to benefit pharmaceutical companies and CROs by offering secure data transmissions between pharmaceutical sponsor and CROs, helping ensure regulatory compliance, enabling reliable audit trails and thereby improving time to market.
Founded in Amman, Jordan, in 1997, IPRC is a privately owned CRO providing clinical services to the pharmaceutical industry in the Middle East and North Africa (MENA) region, Europe and the US.
To date, IPRC has conducted more than 800 bioavailability and bioequivalence studies and has developed and validated 195 bioanalytical methods.
On a daily basis it performs a large number of sample analyses and in order to manage increasing analytical requirements, IPRC needed a LIMS that would enable the company to optimise the reporting of study results while safely archiving all study-related data.
The company selected Thermo Scientific Watson LIMS due to the system's purpose-built functionality for bioanalytical testing applications.
The LIMS has facilitated efficient study design and data transfer between researchers, enabling IPRC to benefit from improved operational efficiency.
The company claims it has also achieved accelerated laboratory turnaround, reduced sample-management costs and regulatory compliance with GLP and 21 CFR Part 11 requirements.
